

**Are abnormalities in lipid metabolism, together with adverse childhood experiences, the silent causes of immune-linked neurotoxicity in major depression?**

(1-10) Michael Maes\*, (3,4,11) Ketsupar Jirakran\*, (3,4) Asara Vasupanrajit, (1,2) Bo Zhou<sup>§</sup>, (3,4,5) Chavit Tunvirachaisakul; (7,8,10) Drozdstoj St. Stoyanov; (1,2,3,12) Abbas F. Almulla<sup>§</sup>

\* Joined first authorships; <sup>§</sup> joined corresponding authors.

1. Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China
2. Key Laboratory of Psychosomatic Medicine, Chinese Academy of Medical Sciences, Chengdu, 610072, China
3. Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
4. Ph.D. Program in Mental Health, Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
5. Cognitive Impairment and Dementia Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
6. Cognitive Fitness and Biopsychological Technology Research Unit, Faculty of Medicine Chulalongkorn University, Bangkok, 10330, Thailand, Bangkok, 10330, Thailand
7. Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria

8. Research Institute, Medical University of Plovdiv, Plovdiv, Bulgaria
9. Kyung Hee University, 26 Kyungheeda-ro, Dongdaemun-gu, Seoul 02447, Korea
10. Research and Innovation Program for the Development of MU - PLOVDIV-(SRIPD-MUP)“, Creation of a network of research higher schools, National plan for recovery and sustainability, European Union – NextGenerationEU.
11. Center of Excellence for Maximizing Children's Developmental Potential, Department of Pediatric, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
12. Medical Laboratory Technology Department, College of Medical Technology, The Islamic University, Najaf, Iraq

**ESF, Table 1.** Overview of the cytokines, chemokines, and growth factors measured in the current study

Protein abbreviations	Gene Symbol	> OOR (%)	Protein name / alias
IFN- $\alpha$ 2	IFNA2	60.8	Interferon- $\alpha$ 2
IFN- $\gamma$	IFNG	81.9	Interferon- $\gamma$
IL-1 $\alpha$	IL1A	60.8	Interleukin-1 $\alpha$
IL-1 $\beta$	IL1B	78.3	Interleukin-1 $\beta$
sIL-1RA	IL1RN	100	Soluble interleukin-1 receptor antagonist
IL-2R	IL2RA	100	Soluble interleukin-2 receptor
IL-4	IL4	100	Interleukin-4
IL-9	IL9	100	Interleukin-9
IL-10	IL10	56.4	Interleukin-10
IL-12p40	IL12B	60.8	Interleukin-12 p40

<b>IL-13</b>	<b>IL13</b>	68.1	Interleukin-13
<b>IL-15</b>	<b>IL15</b>	10.9	Interleukin-15
<b>IL-16</b>	<b>IL16</b>	100	Interleukin-16
<b>IL-17</b>	<b>IL17A</b>	60.8	Interleukin-17
<b>IL-18</b>	<b>IL18</b>	100	Interleukin-18
<b>TNF-α</b>	<b>TNF</b>	100	Tumor necrosis factor-α
<b>TNF-β</b>	<b>LTA</b>	100	Tumor necrosis factor-β or lymphotoxin-alpha (LT-α)
<b>TRAIL</b>	<b>TNFSF10</b>	100	TNF-related apoptosis-inducing ligand (TRAIL) or tumor necrosis factor ligand superfamily member 10 (TNFSF10)
<b>LIF</b>	<b>LIF</b>	94.2	Leukemia inhibitory factor
<b>MIF</b>	<b>MIF</b>	100	Macrophage migration inhibitory factor-like protein (MIF) or glycosylation-inhibiting factor
<b>G-CSF</b>	<b>CSF3</b>	100	Granulocyte colony stimulating factor (G-CSF) or colony stimulating factor 3 (CSF3)
<b>M-CSF</b>	<b>CSF1</b>	100	Macrophage colony-stimulating factor (M-CSF) or colony stimulating factor 1 (CSF1)
<b>GM-CSF</b>	<b>CSF2</b>	60.8	Granulocyte-macrophage colony-stimulating factor (GM-CSF) or colony-stimulating factor 2 (CSF2)
<b>CCL2 or MCP1</b>	<b>CCL2</b>	100	C-C motif chemokine ligand 2 (CCL2) or monocyte chemoattractant protein 1 (MCP1)
<b>CCL3 or MIP-1α</b>	<b>CCL3</b>	100	C-C motif Chemokine ligand 3 (CCL3) or macrophage inflammatory protein 1-alpha (MIP-1α)

<b>CCL4 or MIP-1<math>\beta</math></b>	<b>CCL4</b>	100	C-C motif chemokine ligand 4 (CCL4) or macrophage inflammatory protein 1 $\beta$ (MIP-1 $\beta$ ) or lymphocyte activation gene 1 protein
<b>CCL5 or RANTES</b>	<b>CCL5</b>	100	C-C motif chemokine ligand 5 (CCL5) or regulated upon activation, normally T-expressed, and presumably Secreted (RANTES)
<b>CCL7 or MCP3</b>	<b>CCL7</b>	60.8	C-C motif chemokine ligand 7 (CCL7) or monocyte-chemotactic protein 3 (MCP3).
<b>CCL11 or Eotaxin</b>	<b>CCL11</b>	100	C-C motif chemokine ligand 11 (CCL11) or eosinophil chemotactic protein
<b>CCL27 or CTACK</b>	<b>CCL27</b>	100	C-C motif chemokine ligand 27 (CCL27) or cutaneous T-cell attracting chemokine (CTACK)
<b>CXCL1 or GRO-<math>\alpha</math></b>	<b>CXCL1</b>	100	C-X-C motif chemokine 1 (CXCL1) or growth-regulated alpha protein (GRO)
<b>CXCL8 or IL-8</b>	<b>CXCL8</b>	100	C-X-C motif chemokine ligand 8 (CXCL8) or interleukin-8 (IL-8)
<b>CXCL9 or MIG</b>	<b>CXCL9</b>	100	C-X-C motif chemokine ligand 9 (CXCL9) or monokine induced by gamma interferon (MIG)
<b>CXCL10 or IP10</b>	<b>CXCL10</b>	100	C-X-C motif chemokine ligand 10 (CXCL10) or Interferon gamma-induced protein 10 (IP10)
<b>CXCL12 or SDF-1<math>\alpha</math></b>	<b>CXCL12</b>	100	C-X-C motif chemokine 12 (CXCL12) or stromal cell-derived factor 1 (SDF-1 $\alpha$ )
<b>FGF</b>	<b>FGF2</b>	91.3	Fibroblast growth factor 2 (FGF) or basic fibroblast growth factor
<b>HGF or SF</b>	<b>HGF</b>	100	Hepatocyte growth factor (HGF) or scatter factor (SF)
<b>BNGF</b>	<b>NGF</b>	63.8	$\beta$ -nerve growth factor (NGF)
<b>PDGF</b>	<b>PDGFA</b>	100	Platelet derived growth factor (PDGF)
<b>SCF</b>	<b>KITLG</b>	100	Stem cell factor (SCF) or Kit ligand (KITLG)

SCGF-β or CLEC11A	CLEC11A	100	Stem cell growth factor (SCGF) or C-type lectin domain family 11 member A (CLEC11A)
VEGF	VEGFA	89.1	Vascular endothelial growth factor (VEGF)

Adapted from: *Maes M, Rachayon M, Jirakran K, Sodsai P, Klinchanhom S, Galecki P, Sughondhabiriom A, Basta-Kaim A. The Immune Profile of Major Dysmood Disorder: Proof of Concept and Mechanism Using the Precision Nomothetic Psychiatry Approach. Cells. 2022 Mar 31;11(7):1183. doi: 10.3390/cells11071183. PMID: 35406747; PMCID: PMC8997660.*

*Kalayasiri R, Dadwat K, Supaksorn T, Sirivichayakul S, Maes M. Methamphetamine (MA) use, MA dependence, and MA-induced psychosis are associated with increasing aberrations in the compensatory immunoregulatory system and interleukin-1α and CCL5 levels. medRxiv 2023.03.26.23287766; doi: <https://doi.org/10.1101/2023.03.26.23287766>*

## **ESF, Table 2.** Description of the immune profiles used in this study

Immune Profile	Members
<b>PC05</b>	G-CSF, CXCL1, HGF, sIL-1RA, sIL-2R, IL-4, IL-8, IL-9, IL-16, IL-17, CCL2, MIF, CCL3, CCL4, PDGF, CCL5, SCGF, CXCL12, TNF- $\alpha$ , TNF- $\beta$
<b>PC06</b>	sIL-1RA, IL-4, IL-9, IL-17, CCL4, PDGF, CCL5, CXCL12, TNF- $\alpha$ , TNF- $\beta$
<b>PCdown</b>	CCL3, CSF1, VEGF, NGF, IL-10

PC: principal component

For construction of the PCs:

Maes M, Jirakran K, Vasupanrajit A, Zhou B, Tunvirachaisakul C, Almulla AF. Major depressive disorder, neuroticism, suicidal behaviors, and depression severity are all associated with neurotoxic immune networks and their intricate interactions with metabolic syndrome. medRxiv 2024.01.20.24301553; doi: <https://doi.org/10.1101/2024.01.20.24301553>